First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF®10b

NCT06050356 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

140

Enrollment

OTHER

Sponsor class

Conditions

Healthy

Interventions

BIOLOGICAL: H107e
BIOLOGICAL: CAF®10b
BIOLOGICAL: H107e/CAF®10b - low adjuvant dose
BIOLOGICAL: H107e/CAF®10b - full adjuvant dose
BIOLOGICAL: Low dose intranasal H107e
BIOLOGICAL: Full dose intranasal H107e
BIOLOGICAL: H107e/CAF®10b
BIOLOGICAL: i.m. placebo
BIOLOGICAL: BCG
BIOLOGICAL: i.d. placebo
BIOLOGICAL: Intranasal H107e

Sponsor

Statens Serum Institut

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]